
We invite you to join us on our journey through YUMABS milestones.
Read more »
10th Anniversary Spotlight








On December 3, 2012, Thomas Schirrmann founded the YUMAB GmbH as a spin-off of the University of Braunschweig together with phage display pioneer Stefan Dübel and the scientists André Frenzel and Michael Hust. Their vision was to advance antibody-based drug discovery with services for biotech and pharma R&D based on a unique technology platform. Since then, YUMAB has become a global player in the market for therapeutic antibody discovery and engineering.
Team YUMAB will celebrate the 10th anniversary throughout 2022 by sharing stories of major achievements, business, people, locations, and science with you on this website and we invite you to participate in our activities:
How do you remember YUMAB’s early years? What is your relationship to the company or the people? What’s so typical “YUMAB” that would fit to no other company? What is your message to the team? Please feel free to share memories, anecdotes and pictures with us.
10:00 – 10:15 | Begrüßung & Moderation
Dr. Linda Kirchner & Alexander Ehm, YUMAB GmbH
10:15 – 10:40 | 10 Jahre YUMAB GmbH – Ein Biotech-Unternehmen ist gereift
Dr. Thomas Schirrmann, CEO der YUMAB GmbH
10:45 –11:00 | CORAT – Eine Ausgründung im Kampf gegen COVID-19
Dr. Andreas Herrmann, CEO der CORAT Therapeutics GmbH
11:25 – 11:55 | Antikörperentwicklung mittels Phage-Display Technologie
Antikörperentwicklung mittels Phage-Display Technologie: Erfahren – Bodenständig – Gut
Prof. Dr. Stefan Dübel, Leiter der Abteilung Biotechnologie, Technische Universität Braunschweig Prof. Dr. Michael Hust, Professor Biotechnologie, Technische Universität Braunschweig
12:00 – 12:25 | Translationale Forschung des HZI am Science Campus Braunschweig-Süd
Prof. Dr. Dirk Heinz, Wissenschaftlicher Geschäftsführer des HZI
14:45 – 15:45 | PODIUMSDISKUSSION
Biotech-Standort Braunschweig – Forschungscluster, Innovation, Wachstumsmöglichkeiten
Moderation: Martin Brüning
Leiter Corporate Newsroom, TÜV Nord Group
Dr. Thomas Schirrmann, CEO der YUMAB GmbH
Prof. Dr. Dirk Heinz, Wissenschaftlicher Geschäftsführer, HZI
Gerold Leppa, Wirtschaftsdezernent und Geschäftsführer der Braunschweig Zukunft GmbH Falko Mohrs, Niedersächsischer Minister für Wissenschaft und Kultur
Stephen Struwe-Ramoth, Geschäftsführer der NBank Capital Beteiligungsgesellschaft mbH
15:50 – 16:00 | Zusammenfassung & Schlussworte
Dr. Thomas Schirrmann
Download des Programmheftes
Founding of a biotechnology company by experts and pioneers in recombinant antibody technologies of the University of Braunschweig in Germany.
# of employees: 1
The first time on a conference stage at major trade shows to grab attention which clearly influenced the path and strategy of the YUMAB business model.
# of employees: 2
YUMAB received the IHK Technology Transfer Award for the transfer of antibody generation technologies to industry.
# of employees: 10
For the development of human antibodies, YUMAB and TU Braunschweig received the Innovation Network Lower Saxony Award (1st place).
# of employees: 14
Founding of the US subsidiary to be able to serve the American market more intensively.
# of employees: 14
Open house day with many interesting participants from the press, politics and science.
# of employees: 20
Fighting COVID-19 with recombinant fully human antibodies.
# of employees: 25
Our new logo – 2022 and beyond!
# of employees: 30
partners
antibodies
laboratories m²
babies
conferences
projects
libraries
coffees
dogs
team events
fundings
employees
brainstorming beers
office m2
In the past 10 years, many people have contributed to YUMAB’s success: management & team, collaborators, business partners and clients all enabled independent growth and development from start-up to global player.
As part of the YUMAB community we invite you to write an entry in our 10th anniversary guestbook. Please be aware that the entries will be open to the public and by submitting your entry you agree to publication.
We are looking forward to your contribution!